CA2760219C - Oligomer-containing substituted aromatic triazine compounds - Google Patents

Oligomer-containing substituted aromatic triazine compounds Download PDF

Info

Publication number
CA2760219C
CA2760219C CA2760219A CA2760219A CA2760219C CA 2760219 C CA2760219 C CA 2760219C CA 2760219 A CA2760219 A CA 2760219A CA 2760219 A CA2760219 A CA 2760219A CA 2760219 C CA2760219 C CA 2760219C
Authority
CA
Canada
Prior art keywords
group
oligomer
compound
alkyl
substituted aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2760219A
Other languages
English (en)
French (fr)
Other versions
CA2760219A1 (en
Inventor
Jennifer Riggs-Sauthier
Bo-Liang Deng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CA2760219A1 publication Critical patent/CA2760219A1/en
Application granted granted Critical
Publication of CA2760219C publication Critical patent/CA2760219C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2760219A 2009-05-13 2010-05-13 Oligomer-containing substituted aromatic triazine compounds Active CA2760219C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17793109P 2009-05-13 2009-05-13
US61/177,931 2009-05-13
PCT/US2010/034770 WO2010132691A1 (en) 2009-05-13 2010-05-13 Oligomer-containing substituted aromatic triazine compounds

Publications (2)

Publication Number Publication Date
CA2760219A1 CA2760219A1 (en) 2010-11-18
CA2760219C true CA2760219C (en) 2016-08-16

Family

ID=42557491

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2760219A Active CA2760219C (en) 2009-05-13 2010-05-13 Oligomer-containing substituted aromatic triazine compounds

Country Status (10)

Country Link
US (4) US8772479B2 (enExample)
EP (1) EP2430003B1 (enExample)
JP (1) JP5656980B2 (enExample)
KR (1) KR101799113B1 (enExample)
CN (1) CN102421763B (enExample)
AU (1) AU2010248943B2 (enExample)
CA (1) CA2760219C (enExample)
IL (1) IL216314B (enExample)
MX (1) MX2011012044A (enExample)
WO (1) WO2010132691A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132691A1 (en) 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
DK3261640T3 (da) 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL124029B1 (en) 1979-06-01 1982-12-31 Wellcome Found Process for preparing novel derivatives of 1,2,4-triazine
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US20020182172A1 (en) * 2000-11-30 2002-12-05 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
CN1925875A (zh) * 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
FR2869907B1 (fr) 2004-05-05 2009-02-13 Fabre Pierre Dermo Cosmetique Derives dimeriques de 5,6-diphenyl-1,2,4-triazine et leurs utilisations
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
AU2005281359A1 (en) 2004-08-26 2006-03-16 Apparao Satyam Prodrugs and codrugs containing novel bio-cleavable disulfide linkers
US20060115865A1 (en) * 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20080044438A1 (en) 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
WO2010132691A1 (en) 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds

Also Published As

Publication number Publication date
JP2012526847A (ja) 2012-11-01
WO2010132691A1 (en) 2010-11-18
EP2430003B1 (en) 2019-02-27
US20150065706A1 (en) 2015-03-05
MX2011012044A (es) 2011-12-14
US20120122871A1 (en) 2012-05-17
EP2430003A1 (en) 2012-03-21
US9617228B2 (en) 2017-04-11
KR101799113B1 (ko) 2017-11-17
US9266845B2 (en) 2016-02-23
JP5656980B2 (ja) 2015-01-21
CN102421763A (zh) 2012-04-18
KR20120015311A (ko) 2012-02-21
AU2010248943B2 (en) 2015-05-21
AU2010248943A1 (en) 2011-11-10
US8895553B2 (en) 2014-11-25
CN102421763B (zh) 2015-06-17
US20140256732A1 (en) 2014-09-11
IL216314A0 (en) 2012-01-31
CA2760219A1 (en) 2010-11-18
US8772479B2 (en) 2014-07-08
US20160194294A1 (en) 2016-07-07
IL216314B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
WO2012083153A1 (en) Oligomer-containing apremilast moiety compounds
AU2010202277A1 (en) Chemically modified small molecules
US9399033B2 (en) Oligomer-containing pyrrolidine compounds
US10265411B2 (en) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
US9617228B2 (en) Oligomer-containing substituted aromatic triazine compounds
US9487473B2 (en) Oligomer-amino acid conjugates
US9540330B2 (en) Oligomer-containing hydantoin compounds
US20110009446A1 (en) Oligomer-guanidine class conjugates

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141127

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260413

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260413